OPENING MID-LATE 2018

OCULAR SURFACE SQUAMOUS NEOPLASIA (OSSN)

AMC-104: Feasibility Study of Ocular Surface Squamous Neoplasia (OSSN) Surgical Excision in Sub-Saharan Africa

Participating AMC Sites (provisional)**:** Zimbabwe, Moi, UCI, UNC Project-Malawi

Population*: HIV+ adults, lesions suspicious for OSSN ≤ 7mm in diameter.

_____

***NOTE:** Population descriptions shown do not include all eligibility requirements.

† Additional sites participating in **AMC-066/A5263** can be found on the AIDS Clinical Trials Group public website, https://actgnetwork.org/actg-sites/list?tid=140&=Apply

CONTACTS

For more information on the AMC and its studies or to refer potential participants:

AMC Website: www.amcoperations.com
Email: amipm@emmes.com

Bugando Medical Centre:
Nestory Masalu, MD, MMed
Phone: 255-783-0-00004
nmasalu2000@yahoo.com

Moi University:
Naftali Busakhala, MBChB, MMed
Phone: 254-722-496-933
nbusakhala@yahoo.com

African Cancer Institute, Stellenbosch University:
Vikash Sewram, PhD, MPH
Phone: 27 21 927-7001
vsewram@sun.ac.za

Uganda Cancer Institute (UCI):
Jackson Orem, MBChB, MMED, PhD
Phone: 256-0414-540410
JOrem@mucwru.or.ug

UNC Project-Malawi:
Lameck Chinula, MBBS, FCOG, MMED
Phone: 265-26-517-50610
lameck_chinula@med.unc.edu

University of the Witwatersrand (Wits):
Carla Chibwesha, MD, MSc
Phone: 27-011-276-8850
carla_chibwesha@med.unc.edu

University of Zimbabwe:
Margaret Borok, MBChB, FRCP
Phone: 263-4-791-631
mborok@mweb.co.zw

AMC
AIDS Malignancy Consortium

AFRICAN CLINICAL TRIALS 2017-18

The AMC is a multicenter, U.S. National Cancer Institute-funded, clinical trials group. Its mission is to investigate new treatment and prevention interventions for malignancies in people living with HIV both in the USA and internationally and to study the pathobiology of these tumors in the context of clinical trials.

AMC Clinical Trials sites in Africa are located at:

- Bugando Medical Centre, Mwanza, Tanzania
- Moi University Teaching and Referral Hospital, Eldoret, Kenya
- African Cancer Institute, Stellenbosch University, Cape Town, South Africa
- Uganda Cancer Institute, Kampala
- UNC Project-Malawi, Lilongwe
- University of the Witwatersrand, Johannesburg, South Africa
- University of Zimbabwe, Parirenyatwa Hospital, Harare

OPEN STUDIES

LYMPHOMA

AMC-068: Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-associated Lymphoma in Sub-Saharan Africa. (NCT01775475)

Participating AMC Sites: Moi, Zimbabwe, UCI, UNC Project-Malawi

Population*: HIV+ adults with Diffuse Large B-Cell Lymphoma, no prior chemotherapy, adequate hematologic, renal, hepatic function.

KAPOSI SARCOMA

AMC-066/A5263: A Randomized Comparison of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings (NCT01435018)

Participating AMC Sites: Moi, UNC Project-Malawi, Stellenbosch, Zimbabwe (+ other non-AMC sites†)

Population*: HIV+ adults with advanced KS, no prior chemotherapy, ≤42 days prior ART, adequate hematologic, renal, hepatic, pulmonary function.

OPENING EARLY 2018

KAPOSI SARCOMA

AMC-098: Pilot Study of Nelfinavir for the Treatment of AIDS-KS (NCT03077451)

Participating AMC Sites: UCI

Population*: Adults with KS with or without HIV infection; ECOG PS≤2; adequate hematologic, renal, hepatic function.

AMC-S007: Longitudinal Quality of Life Study Among Participants with AIDS-Associated Kaposi Sarcoma at Bugando Medical Centre, in Mwanza, Tanzania

Participating AMC Sites: Bugando

Population*: HIV+ adults with KS eligible to receive standard chemotherapy with bleomycin and vincristine at Bugando Medical Centre.

CERVICAL CANCER PREVENTION

AMC-099: Randomized, placebo-controlled trial of HPV vaccination to reduce cervical HSIL among HIV-Infected women participating in an HPV test-and-treat program (COVENANT) (NCT03284866)

Participating AMC Sites: All.

Population*: HIV+ women ≥25 years old, on ART ≥6 months, high-risk HPV+, no prior HSIL or HPV vaccine.

OPENING MID-LATE 2018

KAPOSI SARCOMA

AMC-100: Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Infected Individuals with Kaposi Sarcoma (KS) in Sub-Saharan Africa

Participating AMC Sites (provisional)**:** Moi, UNC Project-Malawi, Zimbabwe, UCI, Bugando

Population*: HIV+ adults with KS, on ART for ≥12 weeks, HIV RNA ≤400 c/mL, adequate hematologic, renal, hepatic function; not pregnant; willing to use at least 2 forms of effective contraception.

LOCALLY INVASIVE CERVICAL CANCER

AMC-102: Phase IIB Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Paclitaxel and Carboplatin in HIV-Infected Women with Locally Advanced Cervical Cancer.

Participating AMC Sites: Zimbabwe, Stellenbosch, Wits

Population*: HIV+ women, untreated FIGO stages IIB, IIIA, IIIB, or IVA cervical cancer, adequate hematologic, renal, hepatic function.